13 studies were found.

1.		No longer recruiting	Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia Conditions: adult acute differentiated monocytic leukemia (M5b); adult acute myeloblastic leukemia without maturation (M1); ...
2.		Completed	Comparison of Two Methods in the Treatment of Cytomegalovirus of the Eyes in Patients with AIDS Conditions: Cytomegalovirus Retinitis; HIV Infections
3.		No longer recruiting	Humanized anti-IL-2 receptor monoclonal antibody in moderate-to-severe ulcerative colitis Conditions: Ulcerative Colitis; Gastrointestinal Disease; Inflammatory Bowel Disease
4.		No longer recruiting	A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn’s Disease Conditions: Crohn's Disease; Colitis; Intestinal Disease; Gastrointestinal Disease; Digestive System Disease
5.		No longer recruiting	Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Conditions: recurrent diffuse small lymphocytic/marginal zone lymphoma; recurrent grade III follicular large cell lymphoma; ...
6.		Completed	Pilot Study in Patients with Symptomatic Steroid-Naive Asthma Condition: Asthma
7.		Recruiting	Research Study in Patients With Severe Ulcerative Colitis Condition: Ulcerative Colitis
8.		No longer recruiting	Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease Condition: Graft vs Host Disease
9.		No longer recruiting	Research Study of Visilizumab for Treatment of Glucocorticoid- Refractory Graft Versus Host Disease Condition: Graft-vs-Host Disease
10.		No longer recruiting	Study of Daclizumab in Patients with Chronic, Persistent Asthma Condition: Asthma
11.		Recruiting	To study the effects of CD25 and low dose Cyclosporin in the treatment of active Psoriasis vulgaris Condition: Psoriasis
12.		Recruiting	To study the use of Humanized CD25 in preventing the relapse of Psoriasis Vulgaris Condition: Psoriasis
13.		No longer recruiting	Visilizumab in Treating Patients With Graft-Versus-Host Disease Following Donor Stem Cell Transplantation Condition: Graft Versus Host Disease